DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Thursday morning. The brokerage issued a hold rating on the stock.

DBVT has been the topic of several other research reports. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright lifted their price target on DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Price Performance

Shares of DBV Technologies stock traded up $0.03 during trading hours on Thursday, reaching $0.59. The company had a trading volume of 62,115 shares, compared to its average volume of 229,916. The firm has a market cap of $56.92 million, a PE ratio of -0.65 and a beta of 0.66. DBV Technologies has a one year low of $0.50 and a one year high of $2.14. The business has a fifty day simple moving average of $0.73 and a 200 day simple moving average of $0.89.

DBV Technologies shares are going to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.